8-KLeadership Changes

Medtronic plc 8-K Report, Executive Changes (Feb 19, 2015)

Filed February 19, 2015For Securities:MDT

Summary

This Form 8-K filing from Medtronic plc, dated February 19, 2015, primarily details compensatory arrangements for key executives following the recently completed acquisition of Covidien. The most significant aspect for investors is the employment agreement with Bryan Hanson, who is set to lead the Covidien Business Group. His compensation package includes a substantial base salary, bonus potential, significant stock option and RSU grants totaling $3 million upon hire, and long-term incentive awards. This indicates Medtronic's commitment to integrating the Covidien business and retaining key leadership talent. Additionally, the filing notes an increase in target annual incentive award levels for two other senior officers, Omar Ishrak (CEO) and Gary L. Ellis, effective from the fourth quarter of fiscal year 2015. These adjustments to executive compensation reflect the company's strategic priorities and its approach to incentivizing leadership performance, particularly in the context of post-merger integration and ongoing business operations. Investors should note these changes as they relate to executive compensation and potential shareholder returns.

Key Highlights

  • 1Medtronic plc entered into a letter agreement with Bryan Hanson for his role as Executive Vice President and President, Covidien Business Group.
  • 2Bryan Hanson's compensation includes a $750,000 base salary and an annual bonus target of 85% of base salary.
  • 3Mr. Hanson received sign-on stock option and RSU grants valued at $3 million, subject to vesting criteria, and will be eligible for long-term incentives starting in FY2016.
  • 4A new hire bonus of $1 million is to be paid to Mr. Hanson within 30 days of commencing employment.
  • 5Target award levels for the annual incentive plan (MIP) were increased for Omar Ishrak (CEO) to 175% of base salary and Gary L. Ellis to 120% of base salary, effective Q4 FY2015.
  • 6Prior to Q4 FY2015, the target percentages for Mr. Ishrak and Mr. Ellis were 140% and 90% respectively.
  • 7The compensatory arrangements are being disclosed in the context of the recently completed acquisition of Covidien.

Frequently Asked Questions

The main purpose of this Form 8-K filing is to disclose material changes related to the compensatory arrangements of certain officers of Medtronic plc. Specifically, it details the employment agreement for Bryan Hanson and adjustments to incentive award levels for Omar Ishrak and Gary L. Ellis.

Bryan Hanson's role as President of the Covidien Business Group and his significant compensation package, including a substantial sign-on bonus, stock grants, and incentive opportunities, demonstrate Medtronic's commitment to integrating the acquired Covidien business and retaining key leadership talent to drive its success post-acquisition.

The increased target award levels for the annual incentive plan for Mr. Ishrak and Mr. Ellis indicate a potentially higher bonus payout opportunity tied to company performance, effective from the fourth quarter of fiscal year 2015. This suggests an increased focus on incentivizing executive performance, especially as the company navigates post-acquisition integration and ongoing operations.

The compensation arrangements for Bryan Hanson commenced upon his employment start date of January 26, 2015, with specific bonuses and grants occurring around February 12-18, 2015. The increased target award levels for Omar Ishrak and Gary L. Ellis are effective beginning with the fourth quarter of fiscal year 2015.